Introduction
Desired attributes of vectors for gene therapy include high affinity for the target tissue, suitable promoters to maximize gene expression, proper regulatory elements to synchronize transcription in response to biochemical stimuli and the ability to accommodate the desired transgene of interest. [1] [2] [3] [4] However, after exerting a significant effort to design an appropriate gene delivery vehicle, scientists generally place their novel vector in buffer, add glycerol and store the preparation at −80°C. 5 While this has become standard practice, these conditions could have a detrimental effect on the overall function of a gene delivery system and are not conducive to use of the vector as a medicinal product. Vectors stored under these conditions must be quickly shipped to remote sites on dry ice, which is somewhat costly. This formulation also requires extensive dilution before administration to reduce the toxicity of glycerol.
The goal of the ultimate gene delivery system is to produce transgene expression with maximum safety, effectiveness and reliability. As described above, the molecular and biological aspects of the vector can simultaneously contribute to each of these objectives. The physical and chemical stability of the vector, however, can also significantly affect each goal. As the vector degrades, transduction efficiency drops and the reliability and effectiveness of the preparation diminishes. If the degradation products are toxic or immunogenic, the safety of the preparation is also compromised. Optimization of formulations to enhance chemical and physical stability and prevent degradation of the gene delivery system over time will secure the reliability of the vector preparation. Formulations can also be developed to enhance the transduction efficiency and ultimately the effectiveness of the vector. Obviously, excipients employed in vector formulations must be suitable for use in vivo. Lastly, formulations can also promote vector safety as has recently been described with PEGylated viral preparations. 6, 7 To date, most formulation efforts reported in the literature are focused on the addition of excipients to vector preparations to enhance transduction efficiency in vivo. [8] [9] [10] [11] Few reports describe the physical stability of viral vectors for gene therapy. 12, 13 This report is the first to summarize efforts to systematically develop formulations that enhance the physical and chemical stability of viral vectors at ambient temperature. We chose the adenovirus as our model vector, because it can easily be produced in quantities sufficient for real time assessment of viral stability. Studies were also initiated with adeno-associated virus, as this vector system is becoming increasingly popular for clinical applications. Excipients were selected from a panel of pharmaceutically acceptable compounds known to promote the physical stability of protein and peptide-based therapeutics currently on the market. For a comprehensive review of the principles and theory of the formulation of proteins, the authors refer the reader to a review by Wang. 14 Critical factors that must be considered when developing formulations to enhance vector stability are identified. Important issues for the development of lyophilized preparations are also described. We believe this will serve as a useful reference for the molecular biologist interested in maximizing the reliability and physical stability of novel gene delivery systems before use in the clinic.
Results and discussion

Assessment of formulations for use in frozen and lyophilized viral preparations
Previous work demonstrated that adenovirus titer after a single freeze-thaw cycle was dependent upon the final frozen pH of the cryoprotectant medium. 13 In this report, we assessed two buffers that are acceptable for human use -10 mm sodium phosphate (DPBS) and 10 mm potassium phosphate (KPBS) buffered saline -for their ability to maintain pH at low temperature. The pH of sodium phosphate buffered saline dropped from 7.4 to 5.0 when frozen at −20°C and to pH 4 at −80°C ( Figure  1a) . Addition of glycerol to the buffer did not prevent the drop in pH upon freezing. Differential scanning calorimetry demonstrated that this change in pH is associated with precipitation of buffer components during freezing (Figure 1b) . 15 Addition of sucrose or trehalose to the buffer could not prevent this phenomenon at −80°C, but each sugar at a 1 m concentration did prevent dramatic pH changes at −20°C. Potassium phosphate buffer did not demonstrate the significant changes in pH as seen with the sodium phosphate buffer at −20°C, but did experience similar drops in pH at −80°C. Addition of cryoprotectants did not significantly affect the final pH of the preparation. However, it is important to note that for each buffer system, tertiary amine beta cyclodextrin (TMBCD) could maintain physiological pH upon freezing.
Virus was formulated in the manner described above and frozen at the respective temperature for 24 h. In order to minimize loss due to rapid temperature changes, 13 samples were thawed at 25°C and viral titer assessed in order to determine if change in pH would significantly affect physical stability. Adenoviral preparations were quite sensitive to pH changes upon freezing at the concentration studied (Figure 2a ). Preparations that maintained initial pH (7.4) did not experience significant drops in titer upon thawing. Preparations that underwent a drop of 3 pH units suffered a one log loss of titer. Adeno-associated virus (AAV) was not as sensitive to pH changes upon freezing as the adenovirus at the concentrations studied (Figure 2b ). AAV preparations that experienced a drop of 3 pH units upon freezing lost 0.5 log of infectious virus. As stated above, potassium phosphate buffered saline maintained pH to a higher degree than sodium phosphate buffered saline when frozen at −20°C. Adenovirus stored in 10% glycerol in this buffer system demonstrated superior stability over sodium phosphate buffered preparations ( Figure 2c) . As a result, potassium phosphate buffered saline was the buffer of choice for all formulations unless otherwise indicated.
Stability of Adenoviral Formulations at −20 and 4°C
After screening potential formulations and buffer systems for the ability to maintain pH at low temperature, large scale preparations of formulated virus were stored at −20 and 4°C for a period of 2 years. In order to assess the real-time stability of vector in each formulation, four to six vials from each lot were removed and assessed for transduction efficiency. Expiration dates were assigned to each preparation at the time when titer fell to 90% of its original value (ie suffered 10% loss). [16] [17] [18] Glycerol preparations were the least stable at −20°C. The sodium phosphate buffered preparation lost 10% of the original titer in 2 days (Table 1) . Potassium phosphate buffer extended the shelf life of the virus to 12 days. When glycerol was removed and sucrose added to the preparation, titer did not drop for approximately 1 month. Addition of cyclodextrins to the formulation extended shelf life to 360 (beta cyclodextrin) and 690 (tertiary amine beta cyclodextrin) days which is significantly longer than that of virus in glycerol at −80°C (approximately 37 days, unreported observation). All formulations stored at 4°C significantly enhanced viral stability ( Table 2 ). Sucrose formulations containing beta cyclodextrin and surfactant did not display significant drops in titer for approximately 1 month.
Stability of AAV formulations
Initial stability studies with adeno-associated virus demonstrated that this virus is significantly more stable than the adenovirus. It took approximately 4 months for a preparation stored at 4°C in sodium phosphate buffered saline to lose 10% of the original titer (Table 3) . Similar results were seen at 25°C. A formulation consisting of sucrose, mannitol, Span 20 and protamine extended AAV stability to 5 months at 4 and 25°C. Similar expiration dates were also noted with this formulation at −20 and −80°C.
Effect of formulation on transduction efficiency in vivo
Addition of any substance to a drug product can significantly alter the bioavailability of the active compound. Some excipients can enhance drug absorption. 19 As a result, less medicine is needed to exert the desired effect. Some excipients, however, have been implicated as causing, contributing to, or playing some role in certain human reactions not related to the active compound. The Handbook of Food, Drug, and Cosmetic Excipients has reviewed many of these. 20 Thus, it was imperative that we evaluate formulations that significantly improved vector stability for their effect on transduction efficiency in vivo.
Because adenoviral vectors are suitable for many gene therapy applications, we studied the effect of these formulations on transduction efficiency after intramuscular, intravenous and intratracheal injection in C57BL/6 mice. Transduction efficiency of formulated virus was compared with vector in phosphate buffered saline and the standard 2% glycerol preparation commonly used in preclinical testing of viral vectors. 21 A 5% glycerol formulation was also included as a semi-toxic control by which to compare our formulations. A significant increase in transgene expression was detected after intramuscular injection of the sucrose/beta cyclodextrin and 5% glycerol formulations when compared with that seen in virus formulated in potassium phosphate buffered saline (Student's t test, P р 0.01, Figure 3a) . The other formulations did not significantly effect gene expression in muscle and were well tolerated. While the sucrose/tertiary amine beta cyclodextrin formulation enhanced transduction efficiency of the virus in the lung, transduction efficiency was reduced by the 5% glycerol preparation (Figure 3b ). This effect was not detected in animals given the other formulations. All formulations tested slightly enhanced transduction efficiency when administered intravenously. Table 1 
Development of lyophilized viral vectors
Even though our formulation efforts significantly enhanced adenoviral stability at −20 and 4°C, they would still require shipment on ice. Lyophilization, a technique commonly employed to extend the chemical and physical stability of labile compounds at ambient temperatures, was considered as a practical alternative. The lyophilization process consists of three stages: freezing, primary drying and secondary drying (Figure 4 ). During the freezing step, samples are frozen in the range of −40 to −50°C. When the product is completely frozen, the pressure in the lyophilization chamber is reduced and heat is applied to the product. Under these conditions, water is removed by sublimation, a phase change from the solid state directly to the vapor state without the appearance of an intermediate liquid phase. This is the primary drying phase. After primary drying, additional drying is necessary to remove any water that remains in the product. During secondary drying, heat is slowly added to the highest allowable temperature to maintain product viability and maintained at this level until the process is complete.
Many factors affect product recovery during the lyophilization process. Selection of appropriate excipients that promote stability upon freezing, drying and storage are critical for the success of any lyophilization process. [22] [23] [24] [25] [26] A large batch of adenovirus was purified and divided into five separate groups. Each group was desalted into different formulations. Excipients were selected according to their ability to replace water and form a protective shell around the viral capsid in order to maintain protein conformation during the freezing and drying process as described previously. [27] [28] [29] [30] The initial titer of the lot was 1 × 10 11 lfu/ml. One milliliter aliquots were placed in glass vials and lyophilized under a standard protocol (−40°C for 2 h, −33°C for 12 h, −25°C for 5 h, 10°C for 4 h and 20°C for 8 h at a pressure of 30 mtorr). Preparations lyophilized in sodium or potassium phosphate buffer alone suffered significant losses of 5 and 4 logs of infectious virus respectively ( Figure 5 ). When sucrose, mannitol and Span 20 were added to formulations, titer fell by approximately 1 log. Titer fell by less than 1 log in preparations lyophilized in 1 m sucrose. 
Gene Therapy
Effect of viral concentration on glass transition temperature (TgЈ) of formulations for lyophilization
Even though all excipients significantly improved recovery of adenovirus after lyophilization, each preparation still suffered a drop in titer, which we attribute to the process itself. Thus, formulations were further characterized in order to maximize viral recovery upon completion of the lyophilization cycle. One parameter that is important for ascertaining the required processing conditions is the glass transition temperature (TgЈ), the temperature of maximum freeze concentration where, in a frozen solution, the residual non-ice phase forms a glass. 31 If primary drying is carried out above TgЈ, the freeze concentrate behaves as a viscous liquid, the microstructure of ice formed upon freezing will be lost and product recovery is significantly hampered. If drying occurs below the TgЈ, water will be rapidly removed without disrupting the microstructure established upon freezing which minimizes product loss during lyophilization. 32 Thus, the TgЈ of a preparation sets the safe upper temperature limit for primary drying.
Because TgЈ can vary over an enormous range (−1 to −50°C), determination of this value for a proposed formulation is extremely important and the first step in process development. The TgЈ of a preparation is very concentration-dependent: buffer salts, amino acids, carbohydrates and other components added to a formulation can influence TgЈ. 33 Differential scanning calorimetry (DSC) gives a direct measurement of TgЈ. [34] [35] [36] A representative thermogram is depicted in Figure 6a . Sucrose (1 m) in potassium phosphate buffered saline has a glass transition of −34.5°C (Figure 6b ). When adenovirus was added at a concentration of 1 × 10 11 particles/ml, the TgЈ rose to −33.9°C. Addition of another log of virus increased the glass transition temperature to −32.0°C. This effect is commonly seen with proteins. 22, 37 As protein replaces the water in a preparation, the glass transition rises. Adeno-associated virus had a different effect on the TgЈ of a 0.5 m sucrose formulation. Addition of the virus at a concentration of 1.55 × 10 11 genome copies/ml lowered the glass transition temperature from −33.5 to −34.71°C. Addition of another log of virus dropped TgЈ to −35.37°C. These results suggest that this virus may interact with excipients in the frozen state differently than traditional proteins. Further evaluation of this phenomenon is currently underway in our laboratories. Based on this information, the primary drying temperature for the Ad preparation was set at −35°C. AAV was dried at −38°C.
Effect of final moisture content of the lyophilized cake on the recovery of adenovirus
One of the most critical factors when developing a lyophilized product is the level of residual water in the final product. For many protein preparations, the lower the residual moisture, the more stable the product. [38] [39] [40] Pristoupil et al 41 speculate that residual water disrupts excipient-protein interactions which stabilize conformation in the dry state and therefore interferes with the conformation protection offered by the formulation. It is also possible that excessive water in a preparation promotes conformational flexibility of the protein and the additional water has the ability to mobilize potential reactants in the semi-solid system facilitating chemical degradation and rendering the product unstable.
42,43
Gene Therapy The concept that overdrying a protein will cause loss of activity, although theoretically possible, has little experimental support in the literature. However, Grieff 44, 45 clearly demonstrated that, for influenza virus, stability is optimal at an intermediate water level (1.7%) and that over-drying could promote disruption and aggregation of viral particles, rendering them uninfectious. Keeping this information in mind, we tested the ability of various blends of sucrose and mannitol for final moisture content after a standard lyophilization cycle (−40°C for 2 h, −35°C for 11 h, −10°C for 2 h, 0°C for 2 h and 25°C for 3 h at a pressure of 30 mtorr). When adenovirus was added to these preparations at a concentration of 5.12 × 10 11 lfu/ml, recovery of infectious virus was extremely sensitive to the final moisture content of the product (Table 4) . A preparation of 1:4 sucrose:mannitol had a final moisture content of 0.6% and suffered a 1.1 log loss in viral titer. The 3:4 ratio, with a moisture content of 1.3%, lost less than 1 log of infectious virus. A preparation consisting of a 1:1 ratio of sucrose:mannitol did not experience any loss of titer during the entire lyophilization process. The moisture content of this preparation was 1.4%. If water content rose 0.2% beyond this to 1.6%, titer fell by 2.2 log units. These data indicate that adenovirus is not only sensitive to the final water content in the lyophilized product, but that there is a rather narrow window in which viral titer can be maintained. As a result, all adenoviral lyophilization processes were tailored to produce a final moisture content of 1.3-1.5% in order to afford maximum recovery of virus. The 1:1 formulation consisted of 10 mg/ml sucrose and 10 mg/ml mannitol. Changes in this ratio were made based upon this original formulation, ie the 3:4 ratio consists of 30 mg/ml sucrose and 40 mg/ml manntion, the 1:2 ratio is 10 mg/ml sucrose, 20 mg/ml manntiol, etc. Data are the average of 10 vials from a single lyophilization run.
Effect of virus concentration on recovery of viral titer after lyophilization
If a product still suffers loss in activity after extensive formulation and process development, it is common practice to compensate for the loss by adding additional compound to the preparation before lyophilization. 16, 46 While this practice usually produces products with the desired activity, additional protein could be detrimental to the overall stability of the product particularly during primary drying. High concentrations of protein may induce aggregate formation and precipitation upon freezing resulting in poor recovery of the product. In order to assess the maximum allowable concentration of adenovirus that facilitates optimal recovery of viral titer after lyophilization, adenovirus was lyophilized at two different concentrations in two separate formulations to a final moisture content of approximately 1.4%. This was done to assure that we could truly assess the effect of viral concentration on recovery in the absence of moisture effects (Table 5 ). Preparations at low viral concentration (2-5 × 10 10 lfu/ml) suffered a loss of approximately one log of virus regardless of formulation. The loss in titer was less than one log at higher adenovirus concentrations (2-5 × 10 11 lfu/ml). We believe that this is in part due to the ability of the virus itself to assist in maintaining the final frozen pH of a preparation upon freezing at high concentrations (data not shown). Adenovirus preparations of 1-5 × 10 11 lfu/ml were used in additional lyophilization studies. 
Stability of lyophilized viral vectors
After careful evaluation of process and formulation effects, a large-scale preparation of adenovirus (1 × 10 11 lfu/ml) was lyophilized in a 1 m sucrose formulation under the following protocol: −40°C for 2 h, −35°C for 9 h, −10°C for 4 h, 0°C for 4 h and 25°C for 8 h at a pressure of 30 mtorr. After lyophilization, some vials were reconstituted. The only loss detected in this preparation after 1 year at 4°C was the initial loss of 0.5 log of virus due to the process itself (Figure 7a ). Virus from the same lot prepared in 10% glycerol and stored at −20°C suffered a drop in titer of approximately 2 logs over the same time period. We also assessed the stability of reconstituted preparations stored at 4°C (Figure 7b ). Virus titer dropped at a steady rate of 0.5 log/day over a period of 4 days, indicating that the vector must be used soon after reconstitution. This degradation rate was similar for other lyophilized preparations regardless of formulation (data not shown). Studies to elucidate the nature of this rapid decline in titer and develop novel admixtures for reconstitution which promote viral stability are currently underway. Little work was done with respect to the development of formulations and optimization of the lyophilization process for AAV vectors. In a single experiment, half of an AAV preparation (8.7 × 10 8 lfu/ml) was desalted into potassium phosphate buffered saline. The remaining half was desalted in a formulation of 0.4% sucrose, 0.4% mannitol and protamine. Each preparation was lyophilized under the following protocol: −40°C for 2 h, −38°C for 11 h, −10°C for 2 h, 0°C for 2 h, and 25°C for 3 h at a pressure of 30 mtorr. After an initial loss of 0.3 log in titer due to the lyophilization process, the formulated preparation did not experience any loss in infectivity for 90 days at 25°C (Figure 8 ). It is also important to note that the preparation prepared in buffer without any additional excipients (buffer) experienced a similar loss in titer after lyophilization. This suggests that AAV may be resistant to the stresses of freeze-drying and pose less of a challenge to the formulation scientist with respect to stability.
Development of formulations that enhance vector stability under certain storage conditions is crucial for the success of any gene therapy program. This report provides some insight into factors that affect the chemical and physical stability of viral vectors for gene therapy. The final frozen pH of a formulation significantly affects the titer of both adenovirus and adeno-associated virus preparations. However, this effect can be influenced by Gene Therapy other factors such as the purity of the preparation, initial starting concentration of virus and the rate at which the virus is frozen and thawed. Proper buffer selection and addition of certain excipients to a preparation such as sucrose and cyclodextrins prevent fluctuations in pH upon freezing, and can maintain viral titer for periods of over 1 year at −20°C. Lyophilization of vector preparations can afford remarkable stability at 25°C. Factors that influence viral recovery after lyophilization are excipient selection, vector concentration and residual moisture content of the final dried preparation. Data from AAV preparations suggest that each vector may have its own unique stability profile. In addition, modification of vectors within a group (ie adenovirus deleted of E1 and E4 vs a 'gutless' adenovirus deleted of all virus sequences) may possess different stability profiles from those described here. All most certainly will be different than non-viral vectors, each of which will also have distinct stability profiles. 
Materials and methods
Materials
Sucrose USP, beta cyclodextrin, D-mannitol USP, D(+) trehalose, sorbitan monolaurate (Span 20), and phosphate-buffered saline (PBS) were purchased from Sigma (St Louis, MO, USA). Potassium dihydrogen phosphate (KH 2 PO 4 ), dipotassium hydrogen phosphate (K 2 HPO 4 ), and potassium chloride USP were purchased from JT Baker (Phillipsburg, NJ, USA). Glycerol USP was purchased from EM Science (Gibbstown, NJ, USA). Tertiary amine beta cyclodextrin was purchased from Cerestar USA (Hammond, IN, USA) (current supplier: CarboMer, Westborough, MA, USA). Pluronic block copolymer F68 was kindly provided by the BASF corporation (Mt Olive, NJ, USA). Universal pH indicator was purchased from Fisher Scientific (Pittsburgh, PA, USA).
Preparation of adenovirus
First-generation adenovirus expressing E. coli ␤-galactosidase under the control of a CMV promoter was amplified in 293 cells using a modification of established methods. 47 Virus was purified from cell lysates by banding twice on CsCl gradients followed by desalting on Econo-Pac 10 DG disposable chromatography columns (BioRad, Hercules, CA, USA) equilibrated with each respective formulation. Concentration of the virus was determined by UV spectrophotometric analysis at 260 nm and lac-forming assays (see below). All experiments were performed with freshly purified adenovirus.
Preparation of adeno-associated virus
Production of recombinant AAV2 expressing the E. coli beta-galactosidase gene under the control of a CMV promoter involved transfecting 60% confluent 293 cells in 150 mm dishes with a 1:1:2 ratio of cis plasmid (pAAVlacZ, with AAV ITRs), trans plasmid (p5E18, containing AAV2 Rep and AAV1 Cap) 48 and helper plasmid (pf⌬13, an adenovirus plasmid with most of the late genes deleted and an 8 kb deletion in the E2b region). Transfection was performed by calcium phosphate precipitation. Ninety-six hours after transfection, cells were harvested and subjected to two rounds of CsCl gradient purification as described previously. 49 Virus was desalted by dialysis against respective formulations.
Sample preparation
All formulations were prepared under GLP conditions and sterilized by filtration through a 0.22 m filter (Corning). For all studies, 500-1000 l aliquots were added to autoclaved 3 ml clear borosilicate glass vials (Wheaton, Millville, NJ, USA). Vials were topped with 13 mm gray butyl rubber stoppers (Wheaton) and sealed with tear-off aluminum seals (Wheaton). For pH studies, 10 l of universal pH indicator was added to monitor pH changes during freezing.
pH studies Eight samples were prepared for each formulation as described. Four samples contained universal pH indicator. 13, 50 The remaining samples did not contain the indicator and were used to determine viral titer after freezing. Samples were frozen for 24 h at −20 and −80°C. pH of the frozen products were determined visually and noted for each formulation. Samples not containing indicator were slowly warmed to 25°C and assessed for viral potency.
Stability studies Samples were prepared as described previously. Prior to storage at −20 or 4°C (t = 0), viral titer was determined by lac-forming assay. At each time point, four to six vials were assessed for viral infectivity. Viral titer of each formulation was compared with titer from virus produced in the same lot stored at −20°C in KPBS.
Lyophilization
For each lyophilization study, a lot of virus was divided into two groups with one half desalted in the desired formulation and the other desalted in DPBS containing 10% glycerol. The latter preparation was stored at −20°C and served as a control by which to assess the ability of lyophilization to enhance viral stability. Viral titers were assessed before storage at −20°C and lyophilization (t = 0). Vials containing the formulated preparation were placed in a single shelf research grade lyophilizer (FTS Systems, Stone Ridge, NY, USA) and cooled at a rate of 1°C/min to −40°C. Three vials of formulation without virus were fitted with lead platinum RTD temperature probes (FTS) and placed in the front, middle and back of the lyophilization unit to monitor product temperature changes during the process. After cooling, all samples were lyophilized according to methods tailored to the specific formulation under study. 37 After drying was complete, samples were stoppered under vacuum and sealed with 13 mm tear-off aluminum seals (Wheaton). Samples were stored at 4°C until assayed for viral titer. Lyophilized virus was reconstituted with 1 ml sterile water for injection USP and assayed with samples stored at −20°C in DPBS and 10% glycerol.
Differential scanning calorimetry (DSC)
DSC analysis was performed with a MDSC 2920 (TA Instruments, New Castle, DE, USA) equipped with liquid nitrogen cooling. The calorimeter was calibrated for temperature and cell constant using indium. Fifty microliters of each formulation were analyzed in hermetically sealed aluminum pans (TA Instruments). The cooling rate was 1°C/min. The temperature range was −60 to +25°C. Glass transition values (TgЈ) are reported as the midpoint of the observed transition. Experiments were performed in duplicate.
Moisture analysis
Water content of lyophilized formulations was determined by Karl Fischer titration 51 and confirmed by thermogravimetric analysis (TGA). 52 For Karl Fisher titration, an Aqua Star Karl Fischer titrator (Model C3000, EM Sciences) equipped with a fritless cell was calibrated with Karl Fischer water standard (2-methoxy ethanol) and blanked with the addition of 1 ml anhydrous methanol (EM Sciences). Lyophilized samples were reconstituted with anhydrous methanol and added to the titrator. TGA was performed with a Perkin-Elmer TGA 7 Series thermogravimetric system. Three to five milligrams of lyophilized preparation was scanned at 10°C/min from 25 to 200°C.
Limiting dilution/lac-forming assays
The term lac-forming unit (lfu) defines the number of infectious viral particles present in a preparation of betagalactosidase (lacZ) expressing virus as measured by limiting dilution, infection of 293 cells (or 84-31 cells, a cell line expressing adenovirus E1 and E4 in the case of AAV), 53 histochemical staining and visual identification of beta-galactosidase positive (lac + ) cells. Samples were serially diluted in DMEM supplemented with 2% fetal bovine serum. Medium was removed from 12-well plates seeded with 1.5 × 10 4 cells/well and 0.2 ml of the appropriate dilution was placed on the monolayers. After 2 h at 37°C, 2 ml of complete medium was added to each well and the infection continued for 16 h at 37°C. At this time, medium was removed and cells stained for betagalactosidase expression as described previously. 54 Lac + cells were tallied from a minimum of 20 microscope fields (approximately 48 000 cells). Lac-forming units were calculated as described previously. 13 The sensitivity of the assay is 10 to 1 × 10 13 lfu/ml.
In vivo testing of formulated virus C57BL/6 mice (6-8 weeks old) were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Preparations were administered either via the tail vein (1 × 10 11 particles in 100 l formulation), intratracheally (5 × 10 10 particles in 50 l), or intramuscularly (5 × 10 10 particles in 50 l). Four animals from each group were necropsied either 4 days (intravenous and intratacheal) or 7 days (intramuscular) after injection. Tissues were homogenized in 1 ml of lysis buffer using a Brinkman polytron. Extracts were centrifuged at 14 000 r.p.m. for 10 min. Protein concentration of supernatants was determined with BioRad DC protein assay reagents and bovine serum albumin as a standard. Extracts were quick-frozen in dry ice and stored at −80°C until assayed. ␤-Gal concentrations were determined with an ELISA kit (BoehringerMannheim) according to manufacturer's instructions. Blood samples were collected from remaining animals of each group via the retro-orbital sinus 4 and 7 days after injection for assessment of transaminase levels by an outGene Therapy side contract lab (Antech, New York, NY, USA). All animals were bled before initiation of the study for assessment of baseline transaminases.
